Free tool
FAERS Monitor: Prialt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021060 or its brand name (Prialt, Ziconotide Acetate). Reports on generic versions are filed under their own applications.
Reports
2,435
Serious
1,162
48% of reports
Hospitalization
560
Death reported
121
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain362
- device issue313
- off label use302
- drug ineffective241
- confusional state205
- nausea205
- hallucination168
- dizziness157
- headache136
- hallucination, auditory133
- memory impairment104
- fall101
- vomiting99
- somnolence95
- drug withdrawal syndrome91
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 75 |
| 2006 | 97 |
| 2007 | 102 |
| 2008 | 28 |
| 2009 | 30 |
| 2010 | 37 |
| 2011 | 50 |
| 2012 | 66 |
| 2013 | 61 |
| 2014 | 96 |
| 2015 | 118 |
| 2016 | 392 |
| 2017 | 304 |
| 2018 | 268 |
| 2019 | 211 |
| 2020 | 26 |
| 2021 | 125 |
| 2022 | 82 |
| 2023 | 83 |
| 2024 | 70 |
| 2025 | 74 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,724 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hallucination, auditorySignal | 133 | 72.9 | 61.8 | 9,289 |
| device issueSignal | 313 | 30.2 | 27.3 | 8,830 |
| hallucinationSignal | 168 | 19.3 | 16.7 | 2,900 |
| confusional stateSignal | 205 | 11.0 | 9.6 | 1,860 |
| drug withdrawal syndromeSignal | 91 | 9.0 | 7.3 | 638 |
| memory impairmentSignal | 104 | 6.5 | 5.4 | 486 |
| painSignal | 362 | 5.1 | 4.6 | 1,222 |
| somnolenceSignal | 95 | 4.1 | 3.3 | 220 |
| off label useSignal | 302 | 3.0 | 2.7 | 412 |
| dizzinessSignal | 157 | 2.7 | 2.3 | 173 |
| fallSignal | 101 | 2.6 | 2.2 | 101 |
| nauseaSignal | 205 | 2.2 | 2.0 | 144 |
| headache | 136 | 1.9 | 1.6 | 56 |
| vomiting | 99 | 1.8 | 1.5 | 36 |
| drug ineffective | 241 | 1.6 | 1.4 | 54 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.